World J Urol (2017) 35:1167–1175 DOI 10.1007/s00345-016-1898-z TOPIC PAPER Platinum‑refractory germ cell tumors: an update on current treatment options and developments 1 1 1 1 Christoph Oing · Winfried H. Alsdorf · Gunhild von Amsberg · Karin Oechsle · Carsten Bokemeyer Received: 11 November 2015 / Accepted: 13 July 2016 / Published online: 23 July 2016 © Springer-Verlag Berlin Heidelberg 2016 Abstract and long-term survival in approximately 10–15 %. To Purpose In general, 50 % up to 80 % of metastasized germ date, no molecularly targeted agent has shown reasonable cell tumor patients can be cured by platinum-based chemo- activity. therapy. However, 3–5 % of patients will still die of plati- Conclusions Treatment options for platinum-refractory num-refractory disease and new systemic treatment options disease are limited, but a small subset of patients may are needed to improve treatment success in this difficult achieve long-term disease-free survival by multimodal setting. This review aims to give an overview on treatment treatment. The potential of novel targeted agents, i.e. by options and current developments in the field of platinum- immune-checkpoint-inhibition remains to be defined. refractory male germ cell tumors. Methods A comprehensive literature search was conducted Keywords Germ cell tumor · Germ
World Journal of Urology – Springer Journals
Published: Jul 23, 2016
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera